一种新型通用型牙本质粘结剂对牙本质粘结强度的体外评价

目的:评价一种新型通用型牙本质粘结剂(All Bond Universal,ABU)对牙本质的粘结强度,为临床选择合适的粘结剂提供参考依据。方法:选取人体12颗无龋坏磨牙,磨除牙釉质暴露牙本质面,分别用酸蚀-冲洗法和一步自酸蚀法使用All Bond Universal粘结剂,在其上堆砌树脂,并与酸蚀-冲洗粘结剂Prime&Bond NT(PBN)和一步法自酸蚀粘结剂G Bond(GB)进行对照。试样于37℃去离子水储存24 h后,每颗牙齿垂直于粘结面制备出0.81 mm2的树脂/牙本质试件,进行牙本质粘结微拉伸强度(μTBS)测试。结果:通用型牙本质粘结剂All Bond Universal在两种粘结方法下,其粘结力均高于对照组;就All Bond Universal本身而言,酸蚀-冲洗技术可以提高其粘结强度。结论:这种新型牙本质粘结剂具有较高的粘结强度,并且酸蚀-冲洗技术能提高其粘结力。     

人间鼠疫疫情中基于舆情通的网络舆情监测

目的探索人间鼠疫疫情中网络舆情监测方法,为其他人间鼠疫疫情网络舆情监测提供借鉴。方法基于人间鼠疫疫情中的网络数据,利用舆情通平台分析,对人间鼠疫疫情的网络舆情进行部分展示。结果舆情通系统可监测人间鼠疫疫情的网络舆情变化,通过网络大数据分析获得可视化舆情信息。结论舆情通系统可用于人间鼠疫疫情网络舆情监测,掌握网络舆情的发展和走向,为网络舆情管控赢得时机。     

双瓣法病灶切除术联合子宫动脉阻断术治疗子宫腺肌病及对SDC-1、HPA和VEGF水平的影响

目的 观察腹腔镜下双瓣法病灶切除术联合子宫动脉阻断术治疗子宫腺肌病的治疗效果及其对多配体蛋白聚糖1（syndecan-1,SDC-1）、乙酰肝素酶（heparanase,HPA）和血管内皮细胞生长因子（vascular endothelial growth factor,VEGF）水平的影响。 方法 选取子宫腺肌病患者60例,按照手术方式不同分为观察组和对照组各30例。对照组予以双瓣法病灶切除术,观察组在对照组的基础上予以子宫动脉阻断术。观察2组治疗后临床治疗效果和总有效率;比较2组手术时间、术中出血量、术后腹腔引流量、术后腹腔引流时间、手术前后血红蛋白（hemoglobin,Hb）变化值、住院时间和术后10个月总妊娠率等手术相关指标;观察2组治疗前后月经经期、子宫体积、糖类抗原125（carbohydrate antigen 125,CA125）及SDC-1、HPA和VEGF水平的变化。 结果 观察组临床治疗效果明显优于对照组,总有效率高于对照组,差异均有统计学意义（P＜0.01或P＜0.05）。观察组手术时间、术中出血量、术后腹腔引流量、术后腹腔引流时间、手术前后Hb变化和住院时间明显短于或者少于对照组（P＜0.01）,而术后10个月累积妊娠高于对照组（P＜0.05）。治疗后,2组月经经期、子宫体积和CA125水平均较治疗前明显缩短、减小或降低（P＜0.05）;观察组月经经期、子宫体积和CA125水平较对照组明显缩短、减小或降低（P＜0.01）。治疗后,2组SDC-1、HPA和VEGF水平均较治疗前明显降低,观察组SDC-1、HPA和VEGF水平较对照组明显降低（P＜0.01）。 结论 腹腔镜下双瓣法病灶切除术联合子宫动脉阻断术治疗子宫腺肌病效果显著,可明显缓解痛经,缩小子宫体积,其机制可能与降低机体SDC-1,HPA和VEGF水平有关。     

20株临床来源耐药粪肠球菌的21种耐药元件基因检测与分析

目的：调查20株耐药粪肠球菌株可能存在的耐药基因状况和菌株间的亲缘关系。方法：收集2015年1月—2018年12月湖北省江汉油田总医院住院患者分离的20株耐药粪肠球菌株,用PCR法检测1种青霉素耐药基因、4种氨基糖苷类耐药基因、6种大环内酯类耐药基因、1种链阳菌素耐药基因、2种四环素耐药基因、3种万古霉素耐药基因、2种季胺类消毒剂耐药基因、1种可移动遗传元件标志基因,最后对检测结果作样本聚类分析（UPGMA法）。结果：20株耐药粪肠球菌分别检出1~7种耐药元件基因,包括1种青霉素耐药基因、3种氨基糖苷类耐药基因、2种大环内酯类耐药基因、1种四环素耐药基因、2种万古霉素耐药基因、1种可移动遗传元件标志基因。菌株亲缘关系分析可见20株耐药粪肠球菌可分为A、B 2群。B群又可分为B?1、B?2亚群。B?1亚群有2个克隆播散（4号株?14号株?17号株、8号株与11号株）,B?2亚群有1个克隆播散（9号株与12号株）。结论：青霉素耐药基因、氨基糖苷类耐药基因、大环内酯类耐药基因、四环素耐药基因、万古霉素耐药基因和可移动遗传元件是导致本组粪肠球菌耐药的重要原因。     

Evaluation of Epstein-Barr Virus–Specific Immunologic Response in Solid Organ Transplant Recipients With an Enzyme-Linked ImmunoSpot Assay

Epstein-Barr virus (EBV) is a γ-herpes virus, responsible for infectious mononucleosis in immunocompetent hosts. Cellular immunity appears rapidly during EBV primary infection, keeping it silent despite long-life persistence in B lymphocytes. Defects of the EBV-specific cellular immunity are supposed to be the basis of post-transplantation lymphoproliferative disorders, promoted by high levels of immunosuppression. We retrospectively reviewed 197 solid organ transplant recipients to investigate EBV-specific lymphocyte responsiveness using Enzyme-linked ImmunoSpot assay (EliSpot), which assesses the EBV-specific interferon (IFN)-γ producing peripheral blood mononuclear cells, and kinetics of EBV infection/reactivation post-transplantation using quantitative real-time polymerase chain reaction (PCR) on whole blood. Overall, 102 of the 197 patients (51.8%) showed EBV responsiveness at the EBV-EliSpot assay: 68 (66.6%) showed a persistently positive EBV response in 3 or more determinations and 34 (33.3%) had transient episodes of nonresponsiveness. Ninety-five (48.2%) patients were persistently EBV nonresponders. EBV-DNAemia data were available for 58 patients: 27.6% presented at least one episode of EBV-DNA occurrence. No differences were found in EBV-EliSpot response stratification between the groups of patients who experienced episodes of EBV reactivation and those without EBV-DNAemia. However, EBV DNAemia peak values tended to be higher in the first year post-transplantation in the group of patients with a persistent positive EBV-specific immune response. EBV viral load quantitation in blood and EliSpot EBV-specific immune response determination may represent a powerful tool for monitoring solid organ transplant recipients, guiding immunosuppression modulation in patients with active EBV replication.     

Ex Vivo Lung Perfusion Increases the Pool of Lung Grafts: Analysis of Its Potential and Real Impact on a Lung Transplant Program

Background

Among the strategies to increase the number of lung transplants, ex vivo lung perfusion (EVLP) represents a novel technique to expand the donor pool.

Methods

Data from donors referred to our center were retrospectively analyzed to identify grafts that could potentially be potentially reconditioned by EVLP and for comparison with those obtained by clinical application of EVLP program in our center.

Results

Among 75 rejected lungs, 23 organs have been identified as potentially treatable with EVLP with a hypothetic increase of lung transplant activity of 53%. After the introduction of the EVLP program in our center, lung transplantation with reconditioned grafts was performed in 7 (23%) patients with a 30% increase in transplant procedures.

Conclusion

Although less than expected, EVLP increased the number of lungs suitable for transplantation.